EI
PVLA

EAM Investors’s Palvella Therapeutics PVLA Stock Holding History

EAM Investors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.66M Buy
+29,328
New +$3.06M 0.42% 110
2021
Q4 		– Sell
-3,606
Closed -$1.49M – 393
2021
Q3 		$1.49M Hold
3,606
– – 0.25% 201
2021
Q2 		$1.1M Buy
+3,606
New +$791K 0.17% 283
2018
Q2 		– Sell
-6,518
Closed -$3.56M – 362
2018
Q1 		$3.56M Buy
6,518
+5,198
+394% +$3.22M 0.59% 39
2017
Q4 		$797K Sell
1,320
-749
-36% -$348K 0.14% 234
2017
Q3 		$953K Hold
2,069
– – 0.13% 236
2017
Q2 		$837K Sell
2,069
-215
-9% -$62.8K 0.14% 219
2017
Q1 		$475K Buy
+2,284
New +$404K 0.07% 296

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM Investors's PVLA Position: Q1 2026 in Review

EAM Investors opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 29,328 shares worth $3.66M. The stake represents 0.42% of the portfolio and ranks #110 among its holdings. This is a return to the name: EAM Investors previously reported a position in PVLA as recently as Q3 2021.

EAM Investors first reported a position in PVLA in Q1 2017 and has held it in 8 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • EAM Investors held 29,328 shares of Palvella Therapeutics worth $3.66M as of Q1 2026.
  • Palvella Therapeutics was a new EAM Investors position in Q1 2026.
  • Palvella Therapeutics made up 0.42% of EAM Investors's portfolio in Q1 2026, its #110 holding.
  • EAM Investors first reported a position in Palvella Therapeutics in Q1 2017 and has held it in 8 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.